CA2106474A1 - Polyoxypropylene/polyoxyethylene copolymers with improved biological activity - Google Patents
Polyoxypropylene/polyoxyethylene copolymers with improved biological activityInfo
- Publication number
- CA2106474A1 CA2106474A1 CA002106474A CA2106474A CA2106474A1 CA 2106474 A1 CA2106474 A1 CA 2106474A1 CA 002106474 A CA002106474 A CA 002106474A CA 2106474 A CA2106474 A CA 2106474A CA 2106474 A1 CA2106474 A1 CA 2106474A1
- Authority
- CA
- Canada
- Prior art keywords
- polyoxypropylene
- preparations
- copolymers
- polyoxyethylene
- biological activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/04—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers only
- C08G65/06—Cyclic ethers having no atoms other than carbon and hydrogen outside the ring
- C08G65/08—Saturated oxiranes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
- C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
- C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
- C08G65/2609—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aliphatic hydroxyl groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
- C08G65/2618—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen
- C08G65/2621—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen containing amine groups
- C08G65/2624—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen containing amine groups containing aliphatic amine groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/30—Post-polymerisation treatment, e.g. recovery, purification, drying
Abstract
The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. The preparation entails first condensing propylene oxide to produce a polyoxypropylene polymer and then condensing ethylene oxide with the polyoxypropylene polymer to produce a polyoxypropylene/polyoxyethylene block copolymer of the general formula:
HO(C2H4O)b(C3H6O)a(C2H4O)b H
wherein a and b are integers. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable. The polydispersity of the copolymer is very low, average less than 1.07.
HO(C2H4O)b(C3H6O)a(C2H4O)b H
wherein a and b are integers. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable. The polydispersity of the copolymer is very low, average less than 1.07.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67328991A | 1991-03-19 | 1991-03-19 | |
US673,289 | 1991-03-19 | ||
US84787492A | 1992-03-13 | 1992-03-13 | |
US847,874 | 1992-03-13 | ||
PCT/US1992/002254 WO1992016484A1 (en) | 1991-03-19 | 1992-03-18 | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2106474A1 true CA2106474A1 (en) | 1992-09-20 |
CA2106474C CA2106474C (en) | 2004-02-10 |
Family
ID=27100911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002106474A Expired - Fee Related CA2106474C (en) | 1991-03-19 | 1992-03-18 | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
Country Status (19)
Country | Link |
---|---|
US (7) | US5523492A (en) |
EP (1) | EP0576612B1 (en) |
JP (1) | JP2647556B2 (en) |
KR (1) | KR100224539B1 (en) |
CN (1) | CN1069741A (en) |
AT (1) | ATE187154T1 (en) |
AU (1) | AU662146B2 (en) |
CA (1) | CA2106474C (en) |
CZ (1) | CZ194693A3 (en) |
DE (1) | DE69230372T2 (en) |
DK (1) | DK0576612T3 (en) |
ES (1) | ES2140408T3 (en) |
GR (1) | GR3032726T3 (en) |
HU (1) | HUT67762A (en) |
IE (1) | IE920860A1 (en) |
IL (1) | IL101305A (en) |
NO (1) | NO307890B1 (en) |
SK (1) | SK100893A3 (en) |
WO (1) | WO1992016484A1 (en) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5674911A (en) * | 1987-02-20 | 1997-10-07 | Cytrx Corporation | Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use |
JP2647556B2 (en) * | 1991-03-19 | 1997-08-27 | サイトアーレクス・コーポレーシヨン | Polyoxypropylene / polyoxyethylene copolymers with improved biological activity |
USRE38558E1 (en) | 1991-03-19 | 2004-07-20 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
US6933286B2 (en) | 1991-03-19 | 2005-08-23 | R. Martin Emanuele | Therapeutic delivery compositions and methods of use thereof |
US7202225B1 (en) | 1993-10-15 | 2007-04-10 | Emanuele R Martin | Therapeutic delivery compositions and methods of use thereof |
ZA933926B (en) * | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
US6277410B1 (en) * | 1992-10-08 | 2001-08-21 | Supratek Pharma Inc. | Copolymer compositions for oral delivery |
US6093391A (en) * | 1992-10-08 | 2000-07-25 | Supratek Pharma, Inc. | Peptide copolymer compositions |
US6153193A (en) * | 1993-04-28 | 2000-11-28 | Supratek Pharma Inc. | Compositions for targeting biological agents |
DE69428521T2 (en) * | 1993-02-02 | 2002-05-23 | Xoma Technology Ltd | MEDICINAL COMPOSITIONS CONTAINING A BACTERICIDAL PERMEABILITY-INCREASING PROTEIN AND A SURFACTANT |
KR100361933B1 (en) | 1993-09-08 | 2003-02-14 | 라 졸라 파마슈티칼 컴파니 | Chemically defined nonpolymeric bonds form the platform molecule and its conjugate |
EP0723440B1 (en) * | 1993-10-15 | 2003-01-02 | Cytrx Corporation | Therapeutic delivery compositions and methods of use thereof |
US5932544A (en) * | 1994-05-31 | 1999-08-03 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) compositions |
EP1181937A3 (en) | 1994-08-09 | 2004-02-04 | Cytrx Corporation | Novel vaccine adjuvant and vaccine |
US6353055B1 (en) | 1994-11-18 | 2002-03-05 | Supratek Pharma Inc. | Polynucleotide compositions |
US6221959B1 (en) | 1994-11-18 | 2001-04-24 | Supratek Pharma, Inc. | Polynucleotide compositions |
WO1998013069A2 (en) * | 1996-09-09 | 1998-04-02 | Supratek Pharma, Inc. | Fluorinated copolymeric pharmaceutical adjuncts |
US6942859B2 (en) | 1998-03-13 | 2005-09-13 | University Of Southern California | Red blood cells covalently bound with polymers |
US6312685B1 (en) | 1998-03-13 | 2001-11-06 | Timothy C. Fisher | Red blood cells covalently bound with two different polyethylene glycol derivatives |
WO2000021543A1 (en) * | 1998-10-09 | 2000-04-20 | Cytrx Corporation | Method and composition for treating ischemia and sickle cell anemia |
CA2376057A1 (en) * | 1999-06-08 | 2000-12-14 | La Jolla Pharmaceutical Company | Valency platform molecules comprising aminooxy groups |
US6951939B2 (en) | 2000-06-08 | 2005-10-04 | La Jolla Pharmaceutical Company | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
US20070092526A1 (en) * | 2000-06-23 | 2007-04-26 | Evans Robert K | Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use |
US6761824B2 (en) | 2000-08-17 | 2004-07-13 | Reeve Lorraine E | Process for the fractionation of polymers |
US20040266983A1 (en) * | 2000-08-17 | 2004-12-30 | Reeve Lorraine E | Purified polyoxyalkylene block copolymers |
WO2003079972A2 (en) | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
CA2426582A1 (en) * | 2000-10-20 | 2002-08-08 | Valentis, Inc. | Gene delivery formulations and methods for treatment of ischemic conditions |
US20040009940A1 (en) * | 2000-10-20 | 2004-01-15 | Coleman Michael E. | Gene delivery formulations and methods for treatment of ischemic conditions |
US6492881B2 (en) * | 2001-01-31 | 2002-12-10 | Compaq Information Technologies Group, L.P. | Single to differential logic level interface for computer systems |
NZ529526A (en) * | 2001-04-24 | 2006-06-30 | Purdue Research Foundation | Method and compositions for treating mammalian nerve tissue injuries |
WO2004010941A2 (en) * | 2002-07-29 | 2004-02-05 | Transform Pharmaceuticals, Inc. | Aqueous 2,6-diisopropylphenol pharmaceutical compositions |
US6966990B2 (en) | 2002-10-11 | 2005-11-22 | Ferro Corporation | Composite particles and method for preparing |
JP4917263B2 (en) * | 2002-12-23 | 2012-04-18 | バイカル インコーポレイテッド | Method for lyophilizing nucleic acid / block copolymer / cationic surfactant complex |
EP1581201A4 (en) * | 2002-12-23 | 2011-03-30 | Vical Inc | Method for producing sterile polynucleotide based medicaments |
US7083748B2 (en) * | 2003-02-07 | 2006-08-01 | Ferro Corporation | Method and apparatus for continuous particle production using supercritical fluid |
JP4909071B2 (en) * | 2003-03-24 | 2012-04-04 | プルーローメッド, インコーポレイテッド | Temporary embolization using reverse thermosensitive polymers |
US20060008531A1 (en) * | 2003-05-08 | 2006-01-12 | Ferro Corporation | Method for producing solid-lipid composite drug particles |
EP1663261A2 (en) * | 2003-09-05 | 2006-06-07 | Mannarsamy Balasubramanian | Purified polyoxypropylene/polyoxyethylene copolymers and method of preparing the same |
JP4898447B2 (en) | 2003-10-14 | 2012-03-14 | プルーロームド インコーポレイテッド | Confinement of kidney stone fragments during lithotripsy |
WO2005046438A2 (en) | 2003-11-06 | 2005-05-26 | Pluromed, Inc. | Internal clamp for surgical procedures |
JP4521547B2 (en) * | 2004-04-15 | 2010-08-11 | 株式会社サンメディカル技術研究所 | Blood pump flow estimation device |
US20060134221A1 (en) * | 2004-12-03 | 2006-06-22 | Vical Incorporated | Methods for producing block copolymer/amphiphilic particles |
AU2006216420B2 (en) * | 2005-02-25 | 2010-07-15 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing cardiomyopathy and heart disease |
EP1868652A2 (en) | 2005-04-05 | 2007-12-26 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Method for shielding functional sites or epitopes on proteins |
EP2857041B9 (en) | 2005-05-02 | 2018-02-14 | Genzyme Corporation | Non-lithotripsic kidney-stone therapy |
US8815557B2 (en) * | 2005-07-08 | 2014-08-26 | University Of Chicago | Compositions and methods for refolding of denatured proteins |
WO2008018892A2 (en) * | 2005-12-22 | 2008-02-14 | Pluromed, Inc. | Methods and kits for treating lacerations and puncture wounds using inverse thermosensitive polymers |
WO2008016640A2 (en) * | 2006-08-01 | 2008-02-07 | Phrixus Pharmaceuticals, Incorporated | Use of poloxamer for the prevention and/or treatment of heart failure |
WO2008033728A2 (en) | 2006-09-11 | 2008-03-20 | Pluromed, Inc. | Atraumatic occlusion balloons and skirts, and methods of use thereof |
US20080181952A1 (en) * | 2006-12-11 | 2008-07-31 | Pluromed, Inc. | Perfusive Organ Hemostasis |
BRPI0807558A2 (en) * | 2007-02-22 | 2014-07-01 | Pluromed Inc | Use of Reverse Thermosensitive Polymers to Control the Flow of Biological Fluid Subsequent to a Medical Procedure |
MX2009010778A (en) * | 2007-04-05 | 2010-01-29 | Phrixus Pharmaceuticals Inc | Compositions and methods for the treatment of heart failure. |
EP2185162A4 (en) * | 2007-08-10 | 2012-04-25 | Synthrx Inc | Polymer therapy for the treatment of chronic microvascular diseases |
DK2222697T3 (en) | 2007-11-01 | 2013-03-11 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
EP2219546B1 (en) | 2007-11-29 | 2017-02-01 | Genzyme Corporation | Endoscopic mucosal resectioning using purified inverse thermosensitive polymers |
ES2594302T3 (en) | 2007-12-17 | 2016-12-19 | The Regents Of The University Of Michigan | Compositions and procedures for treatment and prevention of skeletal muscle deficiencies |
EP2350274B1 (en) | 2008-10-21 | 2019-01-23 | The General Hospital Corporation | Cell transplantation |
DE102008043343A1 (en) * | 2008-10-31 | 2010-05-06 | Evonik Goldschmidt Gmbh | Silicone polyether block copolymers with defined polydispersity in the polyoxyalkylene part and their use as stabilizers for the production of polyurethane foams |
WO2010072769A1 (en) | 2008-12-23 | 2010-07-01 | Basf Se | Method for producing polyether block copolymers |
EP3508197A1 (en) | 2009-10-21 | 2019-07-10 | Otonomy, Inc. | Modulation of gel temperature of poloxamer-containing formulations |
GB201008902D0 (en) * | 2010-05-27 | 2010-07-14 | Imp Innovations Ltd | Membrane enhanced polymer sythesis |
EP2601299B1 (en) | 2010-08-06 | 2019-04-24 | The General Hospital Corporation D/B/A Massachusetts General Hospital | System and apparatus for cell treatment |
AU2011329088B2 (en) | 2010-11-15 | 2016-02-25 | Liferaft Biosciences, Inc. | Methods for enhancing oxygenation of jeopardized tissue |
CN103732233B (en) | 2011-03-18 | 2016-08-10 | 贝克斯特国际公司 | Comprise the peritoneal dialysis solution of glucose polymer |
FR2977495B1 (en) * | 2011-07-07 | 2014-03-07 | Sanofi Sa | PHARMACEUTICAL COMPOSITION AND SOLID GALENIC FORM WITH HIGH DRONEDARONE CONTENT AND PROCESS FOR PREPARING THE SAME |
US9662345B2 (en) | 2013-06-14 | 2017-05-30 | Professional Compounding Centers Of America | Antibiotic composition for inhalation and irrigation |
CA2927361A1 (en) | 2013-10-16 | 2015-04-23 | Mast Therapeutics, Inc. | Diuretic induced alterations of plasma volume |
JP6202471B2 (en) | 2013-10-31 | 2017-09-27 | 日油株式会社 | Method for producing medical polyoxypropylene polymer and method for producing medical polyoxypropylene / polyoxyethylene block copolymer |
US20160000823A1 (en) * | 2014-07-07 | 2016-01-07 | Mast Therapeutics, Inc. | Methods and compositions for improving hemostasis |
US9757411B2 (en) | 2014-07-07 | 2017-09-12 | Aires Pharmaceuticals, Inc. | Poloxamer therapy for heart failure |
WO2016007542A1 (en) | 2014-07-07 | 2016-01-14 | Mast Therapeutics, Inc. | Poloxamer therapy for heart failure |
US9403941B2 (en) | 2014-07-07 | 2016-08-02 | Mast Therapeutics, Inc. | Poloxamer composition free of long circulating material and methods for production and uses thereof |
JP6900378B2 (en) * | 2015-12-22 | 2021-07-07 | ビーエイエスエフ・ソシエタス・エウロパエアBasf Se | Method for Purifying Polyether Block Copolymers |
EP3580261A1 (en) | 2017-02-09 | 2019-12-18 | Basf Se | A process for purification of polyether block copolymers |
KR102544922B1 (en) * | 2017-12-21 | 2023-06-16 | 시그마-알드리치 컴퍼니., 엘엘씨 | Poloxamer compositions and methods of making and using the same |
AU2019250128A1 (en) | 2018-10-15 | 2020-04-30 | Avent Inc. | Compositions, systems, kits, and methods for neural ablation |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2979528A (en) * | 1953-10-19 | 1961-04-11 | Wyandotte Chemicals Corp | Nitrogen-containing polyoxyalkylene detergent compositions |
US2674619A (en) * | 1953-10-19 | 1954-04-06 | Wyandotte Chemicals Corp | Polyoxyalkylene compounds |
US3022335A (en) * | 1955-03-30 | 1962-02-20 | Wyandotte Chemicals Corp | Surface active polyoxyalkylene compounds having a plurality of heteric polyoxypropylene-polyoxyethylene chains |
US2854378A (en) * | 1955-12-08 | 1958-09-30 | Bristol Lab Inc | Tetracycline suppository |
US3036118A (en) * | 1957-09-11 | 1962-05-22 | Wyandotte Chemicals Corp | Mixtures of novel conjugated polyoxyethylene-polyoxypropylene compounds |
US3089818A (en) * | 1960-06-02 | 1963-05-14 | Baxter Laboratories Inc | Water dispersible antibiotics |
US3228834A (en) * | 1962-06-08 | 1966-01-11 | Hoffmann La Roche | Pharmaceutical diluent compositions |
US3140232A (en) * | 1962-12-19 | 1964-07-07 | Pfizer & Co C | Color stabilization of tetracycline compositions with polypropylene glycols |
US3391196A (en) * | 1965-08-16 | 1968-07-02 | Wyandotte Chemicals Corp | High equivalent weight hydroxy-terminated ethylene oxide-butylene oxide polyether polyols |
US3740421A (en) * | 1966-09-19 | 1973-06-19 | Basf Wyandotte Corp | Polyoxyethylene-polyoxypropylene aqueous gels |
US3450502A (en) * | 1967-09-25 | 1969-06-17 | Wyandotte Chemicals Corp | Method of operating heart-lung apparatus |
US3641240A (en) * | 1968-09-27 | 1972-02-08 | Wyandotte Chemicals Corp | Method for the treatment of an embolus or thrombus |
US3867533A (en) * | 1968-12-20 | 1975-02-18 | Basf Wyandotte Corp | Preparation of aqueous gel compositions containing a water-insoluble organic ingredient |
US3577522A (en) * | 1969-10-10 | 1971-05-04 | Wyandotte Chemicals Corp | Methods for the treatment of shock with ethylene oxide-polypropylene glycol condensates as blood plasma substitutes |
US3590125A (en) * | 1969-10-10 | 1971-06-29 | Wyandotte Chemicals Corp | Physiological salt solutions of ethylene oxide-polypropylene glycol condensation products as blood plasma substitutes |
US3980772A (en) * | 1969-12-02 | 1976-09-14 | Baxter Laboratories, Inc. | Methods of dissolving blood clots and the like with streptokinase chemically bonded to a carbohydrate matrix |
CA959759A (en) * | 1970-01-15 | 1974-12-24 | John J. Miskel | Method for absorption of drugs |
US3867521A (en) * | 1970-08-26 | 1975-02-18 | Scherer Corp R P | Method for absorption of drugs |
US4073886A (en) * | 1973-01-30 | 1978-02-14 | Baxter Travenol Laboratories, Inc. | Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene |
US3956259A (en) * | 1973-01-30 | 1976-05-11 | Baxter Laboratories, Inc. | Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate |
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US3997458A (en) * | 1974-04-12 | 1976-12-14 | Deknatel, Incorporated | Method of cleansing contaminated wounds and surgical scrub solutions for same |
US4104455A (en) * | 1975-03-25 | 1978-08-01 | Toyo Soda Manufacturing Co., Ltd. | Polymerization of monomer |
US4100271A (en) * | 1976-02-26 | 1978-07-11 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4195167A (en) | 1976-05-28 | 1980-03-25 | Union Carbide Corporation | Gradient polymers of two or more cyclic, organic, ring-opening, addition polymerizable monomers and methods for making same |
JPS545094A (en) | 1977-06-09 | 1979-01-16 | Tokyo Tanabe Co | Production of pharmaceutical urokinase from contamination free human urine |
DE2732929A1 (en) * | 1977-07-21 | 1979-02-01 | Bayer Ag | POLYAETHER, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A LIPID ABSORPTION INHIBITOR |
DE2961374D1 (en) * | 1978-01-27 | 1982-01-28 | Bp Chem Int Ltd | A method for increasing the selectivity to acetic acid in the production of a mixture of c1 to c3 monocarboxylic acids by oxidation of paraffinic hydrocarbons |
DE2808865A1 (en) * | 1978-03-02 | 1979-09-13 | Hoechst Ag | MICROBIOCIDES BASED ON ALKYL DI GUANIDINIUM SALT |
US4275244A (en) * | 1978-05-11 | 1981-06-23 | Basf Wyandotte Corporation | Linear polyalkylene ether glycols of high molecular weight |
JPS5533194A (en) | 1978-08-07 | 1980-03-08 | Scholz D Thomas | Stringgfastener device including tremolant |
US4305922A (en) * | 1978-10-04 | 1981-12-15 | University Patents, Inc. | Labeling proteins with 99m-Tc by ligand exchange |
US4186253A (en) * | 1978-10-10 | 1980-01-29 | The Green Cross Corporation | Perfusate for preserving organ to be transplanted and preserving method |
DE2850058A1 (en) * | 1978-11-18 | 1980-05-29 | Bayer Ag | POLYAETHER DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS |
FR2454409A1 (en) * | 1979-04-18 | 1980-11-14 | Sovam | TRACTOR VEHICLE IN PARTICULAR FOR LARGE CARRIER AIRCRAFT |
FI803077A (en) * | 1979-10-12 | 1981-04-13 | Ciba Geigy Ag | FOERFARANDE FOER FRAMSTAELLNING AV MYRAMYLPEPTIDER |
US4409209A (en) * | 1979-10-12 | 1983-10-11 | Ciba-Geigy Corporation | Novel phosphorylmuramyl peptides and processes for the manufacture thereof |
US4575484A (en) * | 1980-05-05 | 1986-03-11 | Montefiore Medical Center, Inc. | Binding assay for the detection of mycobacteria |
US4410660A (en) * | 1980-05-05 | 1983-10-18 | Montefiore Medical Center | Binding assay for the detection of mycobacteria |
US4489158A (en) * | 1980-05-05 | 1984-12-18 | Montefiore Hospital And Medical Center, Inc. | Binding assay for the detection of mycobacteria |
JPS578223A (en) * | 1980-06-19 | 1982-01-16 | Mitsui Petrochem Ind Ltd | Production of alkylene oxide block copolymer |
US4378347A (en) * | 1980-06-30 | 1983-03-29 | Franco Wayne P | Composition for treating the heart for myocardial infarction |
US4376118A (en) * | 1980-10-06 | 1983-03-08 | Miles Laboratories, Inc. | Stable nonaqueous solution of tetracycline salt |
GR78246B (en) * | 1981-01-23 | 1984-09-26 | Ciba Geigy Ag | |
US4395393A (en) * | 1981-08-10 | 1983-07-26 | Basf Wyandotte Corporation | Artificial blood emulsifiers |
US4407790A (en) * | 1981-09-25 | 1983-10-04 | Economics Laboratory, Inc. | Method of controlling bloat using nonionic surfactants |
US4609546A (en) * | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
DE3234084A1 (en) * | 1982-09-14 | 1984-03-15 | B. Braun Melsungen Ag, 3508 Melsungen | PHARMACEUTICAL PREPARATIONS FOR TREATING UNWANTED GROWTHS AND THEIR USE |
SU1183112A1 (en) * | 1983-08-04 | 1985-10-07 | Научно-Исследовательский Институт Экспериментальной И Клинической Терапии Министерства Здравоохранения Гсср | Method of treatment of acute myocardial ischemia |
US4606918A (en) * | 1983-08-22 | 1986-08-19 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
US4600652A (en) * | 1985-04-01 | 1986-07-15 | Warner-Lambert Company | Permanently bonded antithrombogenic polyurethane surface |
US5183687A (en) * | 1985-06-18 | 1993-02-02 | Emory University | Method of treating poultry for coccidiosis |
US5114708A (en) * | 1985-06-18 | 1992-05-19 | Emory University | Method for stimulating growth in animals |
US4806352A (en) * | 1986-04-15 | 1989-02-21 | Ribi Immunochem Research Inc. | Immunological lipid emulsion adjuvant |
US4803070A (en) * | 1986-04-15 | 1989-02-07 | Ribi Immunochem Research Inc. | Immunological emulsion adjuvants for polysaccharide vaccines |
US5017370A (en) * | 1986-05-15 | 1991-05-21 | Emory University | Improved method of performing angioplasty procedures |
US5047236A (en) * | 1986-05-15 | 1991-09-10 | Emory University | Method of treating stroke |
JPH0610139B2 (en) * | 1986-05-15 | 1994-02-09 | エモリ ユニバーシティ | Mixtures of fibrinolytic compounds and agents for dissolving blood clots in blood vessels |
US4897263A (en) * | 1986-05-15 | 1990-01-30 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
US5089260A (en) * | 1986-05-15 | 1992-02-18 | Emory University | Method of treating ischemic tissue |
US4879109A (en) * | 1986-05-15 | 1989-11-07 | Emory University | Method for treating burns |
US5080894A (en) * | 1986-05-15 | 1992-01-14 | Emory University | Method and composition for reducing tissue damage |
US5028599A (en) * | 1986-05-15 | 1991-07-02 | Emory University | Method of treating mycardial damage |
US4837014A (en) * | 1986-05-15 | 1989-06-06 | Emory University | An improved method of treating sickle cell anemia |
US5064643A (en) * | 1986-05-15 | 1991-11-12 | Emory University | Method for treating sickle cell disease |
US5030448A (en) * | 1986-05-15 | 1991-07-09 | Emory University | Method of delivering drugs to damaged or diseased tissue |
US5032394A (en) * | 1986-05-15 | 1991-07-16 | Emory University | Method of treating burns |
US5198211A (en) * | 1986-05-15 | 1993-03-30 | Emory University | Method of treating myocardial damage |
US4937070A (en) * | 1986-05-15 | 1990-06-26 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
WO1987006831A1 (en) * | 1986-05-15 | 1987-11-19 | Emory University | Composition and method for treating a thrombus and embolus |
US4801452A (en) * | 1986-05-15 | 1989-01-31 | Hunter Robert L | Fibrinolytic composition |
US5250294A (en) * | 1986-05-15 | 1993-10-05 | Emory University | Improved perfusion medium for transplantation of organs |
US5041288A (en) * | 1986-05-15 | 1991-08-20 | Emory University | Method of treating tissue damaged by reperfusion injury |
US5071649A (en) * | 1986-05-15 | 1991-12-10 | Emory University | Method of preventing blockage in catheters |
US4997644A (en) * | 1986-05-15 | 1991-03-05 | Emory University | Method of treating adult respiratory distress syndrome |
US5039520A (en) * | 1986-05-15 | 1991-08-13 | Emory University | Plasma extender |
US5078995A (en) * | 1986-05-15 | 1992-01-07 | Emory University | Fibrionolytic composition |
US4873083A (en) * | 1986-05-15 | 1989-10-10 | Emory University | Fibrinolytic composition |
JP2527942B2 (en) * | 1986-09-18 | 1996-08-28 | ティーディーケイ株式会社 | Magnetic recording media |
US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
US4764567A (en) | 1986-11-20 | 1988-08-16 | Basf Corporation | Process for the preparation of polyoxyalkylene block polyethers having enhanced properties |
AU1396588A (en) * | 1987-02-20 | 1988-09-14 | Emory University | Antiinfective compounds and method of use |
US5811088A (en) | 1987-02-20 | 1998-09-22 | Emory University | Antiinfective compounds and methods of use |
JPH07109520B2 (en) | 1987-02-24 | 1995-11-22 | 株式会社リコー | Electrophotographic photoconductor |
US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
DE4014923A1 (en) * | 1990-05-10 | 1991-11-14 | Basf Ag | PROCESS FOR PRODUCING HARD FOAM MATERIALS CONTAINING URETHANE OR URETHANE AND ISOCYANURATE GROUPS BY THE POLYISOCYANATE POLYADDITIONAL PROCESS AND THE POLYOXYALKYLENE POLYOLS SUITABLE FOR THEM |
JP2647556B2 (en) * | 1991-03-19 | 1997-08-27 | サイトアーレクス・コーポレーシヨン | Polyoxypropylene / polyoxyethylene copolymers with improved biological activity |
US5294365A (en) * | 1991-12-12 | 1994-03-15 | Basf Corporation | Hydroxypolyethers as low-foam surfactants |
US5371253A (en) * | 1993-12-14 | 1994-12-06 | Arco Chemical Technology, L.P. | Process for producing esterified alkoxylated monoglycerides and diglycerides |
-
1992
- 1992-03-18 JP JP4509970A patent/JP2647556B2/en not_active Expired - Fee Related
- 1992-03-18 AT AT92910791T patent/ATE187154T1/en not_active IP Right Cessation
- 1992-03-18 HU HU9302628A patent/HUT67762A/en unknown
- 1992-03-18 CN CN92102964A patent/CN1069741A/en active Pending
- 1992-03-18 CA CA002106474A patent/CA2106474C/en not_active Expired - Fee Related
- 1992-03-18 IE IE086092A patent/IE920860A1/en not_active IP Right Cessation
- 1992-03-18 KR KR1019930702810A patent/KR100224539B1/en not_active IP Right Cessation
- 1992-03-18 AU AU17730/92A patent/AU662146B2/en not_active Ceased
- 1992-03-18 EP EP92910791A patent/EP0576612B1/en not_active Expired - Lifetime
- 1992-03-18 DK DK92910791T patent/DK0576612T3/en active
- 1992-03-18 ES ES92910791T patent/ES2140408T3/en not_active Expired - Lifetime
- 1992-03-18 DE DE69230372T patent/DE69230372T2/en not_active Expired - Fee Related
- 1992-03-18 WO PCT/US1992/002254 patent/WO1992016484A1/en active IP Right Grant
- 1992-03-18 CZ CS931946A patent/CZ194693A3/en unknown
- 1992-03-18 SK SK1008-93A patent/SK100893A3/en unknown
- 1992-03-19 IL IL10130592A patent/IL101305A/en not_active IP Right Cessation
-
1993
- 1993-07-02 US US08/087,136 patent/US5523492A/en not_active Ceased
- 1993-09-17 NO NO933337A patent/NO307890B1/en unknown
-
1996
- 1996-06-03 US US08/657,161 patent/US5691387A/en not_active Ceased
-
1997
- 1997-07-08 US US08/889,342 patent/US5990241A/en not_active Expired - Fee Related
-
1998
- 1998-06-02 US US09/089,043 patent/USRE36665E/en not_active Expired - Lifetime
-
1999
- 1999-08-05 US US09/368,855 patent/US6359014B1/en not_active Expired - Fee Related
- 1999-11-19 US US09/444,417 patent/USRE37285E1/en not_active Expired - Fee Related
-
2000
- 2000-02-23 GR GR20000400425T patent/GR3032726T3/en not_active IP Right Cessation
-
2001
- 2001-12-14 US US10/017,223 patent/US6747064B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2106474A1 (en) | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity | |
CA2006953A1 (en) | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids. | |
GB1390876A (en) | Shapoo composition | |
HUT43488A (en) | Process for preparing polymers decomposing by biological process and utilizable for pharmaceutical purposes | |
EP0835888A3 (en) | Non-crosslinked anion exchange resin and pharmaceutical composition containing same | |
JP3520674B2 (en) | Hair cosmetics | |
NZ243034A (en) | Aqueous hair styling composition comprising a polymer formed from hydrophobic monomers and a water-insoluble volatile diluent for the polymer | |
CA2395493A1 (en) | Hyaluronic acid in the treatment of cancer | |
US5280092A (en) | Lactam-containing emulsifier systems for water-in-oil emulsion polymers | |
IE45370L (en) | Allyl-acrylic monomers and derived polymers | |
GB1414182A (en) | Base for opthalmological medicinal preparations and an opthalmological medicinal film | |
ES8203391A1 (en) | Copolymers having bactericidal activity, process for the preparation thereof and pharmaceutical compositions therefrom | |
US5416158A (en) | Crosslinked carboxylic copolymers useful as rheological additives in personal care and pharmaceutical products | |
DK0517160T3 (en) | Ophthalmic extended release preparations | |
DE3373417D1 (en) | Use of a sulfonated homo- or copolymer of styrene for the manufacture of a contraceptive composition | |
FI925570A (en) | The cationic copolymer, which disperses and alternates with the best crystallization of the paper | |
WO1993014024A1 (en) | Hair care compositions | |
IT7825994A0 (en) | COATING COMPOSITION PROCEDURE FOR THE PREPARATION OF A LIQUID HAVING A HIGH CONTENT OF AN ACRYLATE COPOLYMER OF LOW IN SOLID PRODUCTS BASED ON THE MOLECULAR WEIGHT, AND OF AN ACRYLATE COPOLYMER SO OBTAINED. | |
FR2403353A1 (en) | NEW DERIVATIVES OF POLYASPARTIC ACID, THEIR PREPARATION AND THEIR USE IN COSMETIC COMPOSITIONS | |
MY103428A (en) | Hairdressing composition | |
RU93056161A (en) | BLOCK-COPOLYMER POLYOXYPROPYLENE AND POLYOXYETHYLENE, SURFACE-ACTIVE COPOLYMER, METHOD OF OBTAINING NONTOXIC SURFACE-ACTIVE COPOLYMER, MEDICINE | |
JPS54138129A (en) | Gelatinous or creamy composition | |
JPS62281810A (en) | Separation-type liquid hair-dressing composition | |
IE922400L (en) | Composition comprising an oxygen radical scavenger and a¹surface-active copolymer | |
JP2000327522A (en) | Cosmetics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |